Navigation Links
Exiqon Announces 2009 North American Grant Award Winners
Date:7/1/2009

led experimental plans, including how each would implement research tools from Exiqon. The two winners were faced with strong competition. Submission statistics for the grant program, divulged by Exiqon, revealed a significant response from the research community at large, including nearly 200 informational requests, and more than 90 qualified applications received as of June 15th, the program's deadline.

"The level of response we have received to this program has, quite frankly, exceeded our initial expectations," said Chris Harbert, Director of Marketing, Exiqon North American Life Sciences. "The range of pathologies indicated in the pool of applications clearly illustrates the importance of microRNA investigation in current biomedical research, and reaffirms the strong need for available tools and funding opportunities in this field. We are very proud to help support Dr. Zhang and Dr. Sugatani seek new breakthroughs in microRNA research. It will be exciting to see what unfolds."

The two award winners will split the grant program seed funding of $25,000. Both grant finalists may use Exiqon Grant Program awards for the purchase of any Exiqon microRNA product or service. Exiqon offers a complete product line for microRNA investigation, including products for RNA isolation, Microarray analysis, qRT-PCR analysis, Northern Blotting, In Situ Hybridization, and Knockdown studies. Exiqon also offers microRNA profiling services for both microarray and qRT-PCR analysis, complete with full sample QC and customized data analysis and reporting.

Additional information:
Additional information is available through Exiqon representatives located across North America. Interested parties are invited to contact Exiqon at 1-888-647-2879.

Information is also available from these web pages:

Fuchs Laboratory of Mammalian Cell Biology & Development

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Exiqon Announces New Grant Program for MicroRNA Research
2. The Meetings Industry...Stirred But Not Shaken by Current Economic Setbacks - Patriot Meetings Announces Their 360 Degree Program that Ensures Successful Meetings
3. Medco Announces Date for Second-Quarter 2009 Financial Results
4. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
5. Anixter Center Announces Leadership Changes
6. Availity Announces Strategic Relationship With Anthem Blue Cross and Blue Shield in Kentucky
7. AIUM announces management agreement with the International Society of Therapeutic Ultrasound
8. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
10. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
11. YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System.

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Exiqon Announces 2009 North American Grant Award Winners 
Exiqon Announces 2009 North American Grant Award Winners
(Date:11/20/2009)...nderstanding Brain Wiring and Diseases ,, WASHI...my Schmahmann, Professor of Neurology at Harvard M... General Hospital in Boston, on Thursday, November...w field of study called "Connectivity" at the laun...n is an award-winning leader in the field of the c...
(Date:11/20/2009).../ -- Following a recall by Unilever The Stop &...s Country Crock ® Side Dishes DELUXE Cheddar ...e Dishes DELUXE Four Cheese Pasta due to an undecl...ates and UPCs are affected: ,, Shedd,s Country...Rice 21 oz, UPC 027400218316, Best By NOV 29 09 th...
(Date:11/20/2009)...FirstCall/ -- Centene Corporation (NYSE: CNC )...of America Merrill Lynch 2009 Credit Conference, t...Hotel Times Square in New York City. ,, Centene... Eastern Time. Investors and other interested part...presentation at: http://www.veracast.com/webcasts...
(Date:11/20/2009)...-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI ) ...dio Reports: What Every Women Needs to Know About...n journalist Perri Peltz. ,, (Logo: http://ww...,, Doctor Radio Reports: What Every Woman Ne...21 live at 10:00 am ET on Doctor Radio , SIRIUS c...
(Date:11/20/2009)...gency medical service (EMS) providers in the Unite...ts each year. Only 5 to 10 percent of people who ...y cardiopulmonary resuscitation (CPR) provided by ...etter patient outcome. The Resuscitation Outcomes... network to study prehospital treatments for cardi...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...sue swelling better than steroids, team says , ...-angiogenesis drugs reduce edema (swelling of brai...oblastomas, a new study suggests. , Anti-angiogene...ospital team found that the experimental anti-angi...
...ill be made available closer to the meeting date. ...ance of the meeting as well as during the meeting....esearch Council of the National Academy of Science...ip of more than 5,700 scientists is representative...
... April 2 /PRNewswire-Asia-FirstCall/ -- Genesis,Ph...d: GNPH) ("Genesis" or the,"Company"), a U.S. phar...n the,People,s Republic of China, today affirmed i...e guidance for its fiscal year ending June,30, 200...
...e Treatment by a Podiatrist May Lead to Long-Term ...oot problems such as bunions, corns and dry, crack...e particular ailment -- heel pain -- stands out am...20 Americans aged 18 and older, found that 39 perc...
... Corticon offers special pricing on patent-pe...nd managing engaging self-service web applications...EB) April 2, 2009 -- Corticon Technologies, Inc. (...nar about, its patent-pending Corticon DialogsTM ...
... Celebrity Stylist, Lauri Eisenberg, Offers H...n Doesn,t Control Your Wardrobe , ...you,d never consider wearing silk or even solid co... waterworks going on underneath, then perspiration...
Other Medicine News:Health News:Drug Improves Survival in Mice With Brain Tumors 2Health News:Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009 2Health News:Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts Revenue Guidance for Fiscal 2009 3Health News:Survey Shows Nearly 40 Percent of Americans Reel From Heel Pain 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Don't Sacrifice Style Because of Sweat 2Health News:Don't Sacrifice Style Because of Sweat 3Health News:Don't Sacrifice Style Because of Sweat 4
(Date:11/20/2009)...irstCall/ -- Medco Health Solutions, Inc (NYSE: ... American healthcare through an advanced, wired ph...quality clinical care and fundamentally bending th...or the benefit of patients and payors alike. ,,...ts strategy enable "Smarter Medicine" to help addr...
(Date:11/20/2009)...re/ -- Reportlinker.com announces that a new marke..., Pipettes & Pipettors - A Global Market P...164373/Pipettes--Pipettors---A-Global-Market-Persp...r&utm_campaign=prnewswire ,, Pipettes and...research laboratory. Large-scale applications in l...
(Date:11/20/2009)...re/ -- Reportlinker.com announces that a new marke..., Medical Adhesives and Sealants - A US Market...242/Medical-Adhesives-and-Sealants---A-US-Market-R...&utm_campaign=prnewswire ,, The use of me...e in medical devices and equipments. Cutting edge ...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Insurance and HMO Industries Spend Nearly 24700 000 Per Day to Kill Health Care Reform Measures 57243 1Insurance and HMO Industries Spend Nearly 24700 000 Per Day to Kill Health Care Reform Measures 57243 2Sigma Aldrich to Present at the UBS Global Life Sciences Conference on Monday September 21 2009 14064 1Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 1Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 2Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 57234 3
...07 - Clinical results from a,Phase II study presen...ciety (AHS) annual meeting showed that MK-0974, an...ide (CGRP),receptor antagonist, significantly impr...ompared to placebo, and the relief was,sustained t...ted in,the study. Responses specific to other meas...
... weeks achieved an SVR rate at,least comparable to...e favorable quality-of-life scores -, ROCKVILLE, M...Genome Sciences, Inc. today announced the top-line...uferon(R) (albinterferon alfa-2b),in combination w...otype 1 chronic hepatitis C. The Company expects t...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
Lumenis 950 Slit Lamp
Novus 3000 532 nm Laser System
Selecta Duo Photocoagulator Combination Laser
EnTrust Single Chamber ICD
Medicine Products: